We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Researchers Will Have Ready Access to Molecular Diagnostics Expertise at the AACC Clinical Lab Expo

By LabMedica International staff writers
Posted on 30 Jul 2013
Print article
Image: Nebsolutions expertise promotes molecular diagnostic development (Photo courtesy of New England Biolabs).
Image: Nebsolutions expertise promotes molecular diagnostic development (Photo courtesy of New England Biolabs).
Biotech and other life science researchers will be able to consult with a team of molecular diagnostics (MDx) experts at the AACC (American Association for Clinical Chemistry) Clinical Lab Expo in Houston (TX, USA), from July 30-August 1, 2013.

The New England Biolabs (Ipswich, MA, USA) NEBsolutions team of experts will be available at booth 4463 during the Lab Expo meeting. The team is in place to direct access to expertise in enzymology, supply logistics, custom formulations, packaging, and kit development and to maximize access to New England Biolabs' catalogue of high-quality reagents. New England Biolabs provides reagents for a variety of MDx applications, such as sample preparation, PCR, RT-PCR, isothermal amplification, methylation detection, and library preparation for next generation sequencing.

NEBsolutions, a dedicated team within the New England Biolabs framework, comprises 110 PhDs, more than half with greater than 10 years of tenure at New England Biolabs. They provide the highest level of support to meet the specific needs of New England Biolabs' OEM and customized product customers. The NEBsolutions team excels at meeting aggressive timelines and offers rapid lead-times. This includes leveraging the capabilities of the entire company to help customers achieve their goals. The NEBsolutions team will work to optimize reagent formulation, function, and manufacturing process, resulting in an optimized product while minimizing cost.

"New England Biolabs has been supplying high-quality reagents to the molecular diagnostics community since 1995," said John Pelletier, director of NEBsolutions. "Through the NEBsolutions team, you gain access to NEB’s broad array of resources, including the deep scientific know-how to functionally optimize your product, comprehensive experience in the manufacturing of high-quality products, and extensive experience in supply chain management and risk mitigation. Our quality-by-design approach ensures product performance and consistency that surpass customer needs."

Related Links:
New England Biolabs
NEBsolutions


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultrasonic Cleaner
UC 300 Series
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.